Abstract |
Bispecific antibodies (bsAb) have attracted much attention over the past several years as a mean to improve immunotherapy of cancer. Due to their dual specificity, bsAb are able to redirect effector cells against tumor targets. In this study, the development and preclinical testing of a new quadroma-derived bsAb, HEA125x197, recognizing the tumor-associated Ep-CAM antigen and the high affinity Fc receptor for IgG, CD64, is reported. Using granulocyte-colony stimulating factor ( G-CSF) and interferon-gamma (IFN-gamma)-stimulated polymorphonuclear neutrophils to induce CD64 expression, bsAb HEA125 x 197 elicited strong cytotoxic activity towards allogeneic and autologous ovarian carcinoma cells. The cytolytic efficiency of this antibody was comparable to that of a previously described bsAb, HEA125 x OKT3, targeting preactivated T lymphocytes against Ep-CAM-carrying tumor cells. Based on the pan- carcinoma specificity and the stable expression of Ep-CAM, bsAb HEA125x197 may broaden the spectrum of bispecific reagents for the treatment of epithelial malignancies.
|
Authors | Christof Schweizer, Gudrun Strauss, Matthias Lindner, Alexander Marmé, Yashwant M Deo, Gerhard Moldenhauer |
Journal | Cancer immunology, immunotherapy : CII
(Cancer Immunol Immunother)
Vol. 51
Issue 11-12
Pg. 621-9
(Dec 2002)
ISSN: 0340-7004 [Print] Germany |
PMID | 12439607
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antibodies, Bispecific
- Antigens, Neoplasm
- Cell Adhesion Molecules
- Epithelial Cell Adhesion Molecule
- Receptors, IgG
|
Topics |
- Adenocarcinoma
(pathology, therapy)
- Antibodies, Bispecific
- Antigens, Neoplasm
(immunology)
- Cell Adhesion Molecules
(immunology)
- Cytotoxicity, Immunologic
- Epithelial Cell Adhesion Molecule
- Female
- HL-60 Cells
- Humans
- Neutrophils
(immunology)
- Ovarian Neoplasms
(pathology, therapy)
- Receptors, IgG
(immunology)
- T-Lymphocytes
(immunology)
|